MA42622B1 - Agents de liaison à tigit et leurs utilisations - Google Patents

Agents de liaison à tigit et leurs utilisations

Info

Publication number
MA42622B1
MA42622B1 MA42622A MA42622A MA42622B1 MA 42622 B1 MA42622 B1 MA 42622B1 MA 42622 A MA42622 A MA 42622A MA 42622 A MA42622 A MA 42622A MA 42622 B1 MA42622 B1 MA 42622B1
Authority
MA
Morocco
Prior art keywords
tigit
agents
liaisons
relates
antibodies
Prior art date
Application number
MA42622A
Other languages
English (en)
Other versions
MA42622A (fr
Inventor
Austin Gurney
Ming-Hong Xie
Original Assignee
Mereo Biopharma 5 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 5 Inc filed Critical Mereo Biopharma 5 Inc
Publication of MA42622A publication Critical patent/MA42622A/fr
Publication of MA42622B1 publication Critical patent/MA42622B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des agents qui se lient spécifiquement à tigit. Les agents de liaison à tigit peuvent comprendre des polypeptides, des anticorps et/ou des agents bispécifiques. L'invention concerne également des procédés d'utilisation de ces agents pour améliorer la réponse immunitaire et/ou pour le traitement de maladies telles que le cancer.
MA42622A 2015-05-28 2016-05-27 Agents de liaison à tigit et leurs utilisations MA42622B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562167582P 2015-05-28 2015-05-28
US201562205279P 2015-08-14 2015-08-14
US201662313487P 2016-03-25 2016-03-25
PCT/US2016/034549 WO2016191643A2 (fr) 2015-05-28 2016-05-27 Agents de liaison à tigit et leurs utilisations

Publications (2)

Publication Number Publication Date
MA42622A MA42622A (fr) 2018-06-20
MA42622B1 true MA42622B1 (fr) 2021-11-30

Family

ID=57393726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42622A MA42622B1 (fr) 2015-05-28 2016-05-27 Agents de liaison à tigit et leurs utilisations

Country Status (29)

Country Link
US (2) US10112997B2 (fr)
EP (2) EP4011907A1 (fr)
JP (2) JP6875295B2 (fr)
KR (1) KR20180014050A (fr)
CN (2) CN115429877A (fr)
AU (1) AU2016267577B2 (fr)
BR (1) BR112017025529A2 (fr)
CA (1) CA2987607A1 (fr)
CL (1) CL2017003021A1 (fr)
CO (1) CO2017012342A2 (fr)
CY (1) CY1125260T1 (fr)
DK (1) DK3303379T3 (fr)
EC (1) ECSP17083779A (fr)
ES (1) ES2902150T3 (fr)
HR (1) HRP20211948T1 (fr)
HU (1) HUE057087T2 (fr)
IL (1) IL255577B (fr)
LT (1) LT3303379T (fr)
MA (1) MA42622B1 (fr)
MD (1) MD3303379T2 (fr)
MX (1) MX2017014955A (fr)
NZ (1) NZ738008A (fr)
PL (1) PL3303379T3 (fr)
PT (1) PT3303379T (fr)
RS (1) RS62815B1 (fr)
SA (1) SA517390370B1 (fr)
SI (1) SI3303379T1 (fr)
TW (1) TWI715587B (fr)
WO (1) WO2016191643A2 (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TN2017000024A1 (en) 2014-08-19 2018-07-04 Merck Sharp & Dohme Anti-tigit antibodies.
EP3237448A1 (fr) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Anticorps contre tigit
CA2976926A1 (fr) 2015-02-19 2016-08-25 Compugen Ltd. Anticorps anti-pvrig et methodes d'utilisation
EP3978929A1 (fr) 2015-02-19 2022-04-06 Compugen Ltd. Polypeptides pvrig et méthodes de traitement
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2017037707A1 (fr) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps spécifiques contre le domaine d'immunoglobuline de lymphocyte t et itim (tigit)
AR109625A1 (es) 2015-10-01 2019-01-09 Potenza Therapeutics Inc Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
TW202409084A (zh) 2016-03-04 2024-03-01 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
CN109715657A (zh) 2016-04-15 2019-05-03 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
JP7267012B2 (ja) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド 抗ｔｉｍ－３抗体及びその使用方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd112 et utilisations associées
TWI760352B (zh) 2016-08-09 2022-04-11 英商克馬伯有限公司 抗ｉｃｏｓ抗體
IL301682A (en) * 2016-08-17 2023-05-01 Compugen Ltd Antibodies against TIGIT, antibodies against PVRIG and their combinations
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
WO2018128939A1 (fr) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
CN110168078B (zh) * 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
MX2019010206A (es) * 2017-02-28 2019-12-11 Seattle Genetics Inc Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
EP3596115A1 (fr) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants pd-l2 et utilisations associées
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018187191A1 (fr) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions et procédés de traitement du cancer
US11760777B2 (en) 2017-04-26 2023-09-19 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
AU2018276140A1 (en) 2017-06-01 2019-12-19 Compugen Ltd. Triple combination antibody therapies
WO2018229163A1 (fr) 2017-06-14 2018-12-20 King's College London Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN111093696B (zh) * 2017-07-17 2023-10-27 詹森生物科技公司 抗iii型纤连蛋白结构域的抗原结合区及其使用方法
WO2019023504A1 (fr) 2017-07-27 2019-01-31 Iteos Therapeutics Sa Anticorps anti-tigit
ES2812236T3 (es) * 2017-07-27 2021-03-16 iTeos Belgium SA Anticuerpos anti-TIGIT
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
EP3689909A4 (fr) * 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Anticorps tigit, fragment de liaison à l'antigène de celui-ci, et son utilisation médicale
WO2019074983A1 (fr) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
EP3697810A2 (fr) 2017-10-18 2020-08-26 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
WO2019079777A1 (fr) * 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center Compositions et procédés d'immunothérapie ciblant tigit et/ou cd112r ou comprenant la surexpression de cd226
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
US11708410B2 (en) * 2018-01-15 2023-07-25 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
CA3097593A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Proteines de fusion heterodimeres ciblant pd-1 contenant des proteines de fusion fc d'il-15/il-15ra, domaines de liaison a l'antigene pd-1 et utilisations associees
MX2020010912A (es) 2018-04-18 2021-01-29 Xencor Inc Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas.
EP3813864A4 (fr) 2018-06-29 2022-07-20 Gensun Biopharma Inc. Antagonistes antitumoraux
US11370837B2 (en) * 2018-07-25 2022-06-28 Innovent Biologics (Suzhou) Co., Ltd. Anti-TIGIT antibody and use thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
PE20211055A1 (es) 2018-10-12 2021-06-07 Xencor Inc Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
KR20210113282A (ko) * 2019-01-07 2021-09-15 아이테오스 벨지움 에스에이 항-tigit 항체
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
US20220146500A1 (en) * 2019-02-27 2022-05-12 Yale University Compositions and methods for enhancing mucosal immunity
EP3938396A1 (fr) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anticorps anti-icos pour le traitement du cancer
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
MX2021013850A (es) * 2019-06-13 2022-01-07 Green Cross Corp Anticuerpo contra tigit y uso del mismo.
JP2022537053A (ja) * 2019-06-21 2022-08-23 シングル セル テクノロジー， インコーポレイテッド 抗ｔｉｇｉｔ抗体
US20220267475A1 (en) * 2019-06-25 2022-08-25 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
WO2020263312A1 (fr) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFβ1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
US11667709B2 (en) 2019-09-24 2023-06-06 Industrial Technology Research Institute Anti-TIGIT antibodies and methods of use
WO2021062332A1 (fr) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Association d'inhibiteurs de la signalisation de l'il4 et de points de contrôle immunitaires pour le traitement du cancer
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021091960A1 (fr) 2019-11-05 2021-05-14 Jounce Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
EP4157875A1 (fr) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Anticorps anti-tigit
WO2021258337A1 (fr) * 2020-06-24 2021-12-30 Huahui Health Ltd. Anticorps monoclonaux humains dirigés contre tigit pour des maladies immunitaires
EP4178611A1 (fr) 2020-07-07 2023-05-17 BioNTech SE Arn thérapeutique contre le cancer positif au vph
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用
CN112190689B (zh) * 2020-08-25 2022-12-09 沣潮医药科技（上海）有限公司 Tigit免疫粘附素在调控肿瘤免疫及调节血管生成产品中的应用
EP4253414A4 (fr) * 2020-10-26 2024-10-16 Akeso Biopharma Inc Anticorps anti-tigit, composition pharmaceutique et utilisation correspondante
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
WO2022111612A1 (fr) * 2020-11-26 2022-06-02 信达生物制药(苏州)有限公司 Préparation comprenant un anticorps bispécifique anti-tigit/pd-1, son procédé de préparation et son utilisation
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
WO2022217026A1 (fr) 2021-04-09 2022-10-13 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit
WO2022214653A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées
AU2022261268A1 (en) 2021-04-22 2023-11-16 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
EP4339208A4 (fr) * 2021-05-10 2024-07-24 Medimabbio Inc Anticorps anti-tigit et leur utilisation
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
WO2023001303A1 (fr) * 2021-07-23 2023-01-26 中山康方生物医药有限公司 Composition pharmaceutique et son utilisation
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN116284390A (zh) * 2021-12-21 2023-06-23 广东安普泽生物医药股份有限公司 人tigit抗体及其应用
WO2023149977A1 (fr) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Méthodes de traitement du cancer
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
TW202409083A (zh) 2022-05-02 2024-03-01 美商阿克思生物科學有限公司 抗-tigit抗體及其用途
KR20230168598A (ko) * 2022-06-03 2023-12-14 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024163477A1 (fr) 2023-01-31 2024-08-08 University Of Rochester Thérapie de blocage de point de contrôle immunitaire pour le traitement d'infections par staphylococcus aureus
WO2024191807A1 (fr) 2023-03-10 2024-09-19 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit
WO2024200823A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation
WO2024200820A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Procédé de synthèse de nanoparticule lipidique ciblée et ses utilisations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP2388265A1 (fr) 2002-02-22 2011-11-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
ATE493433T1 (de) 2002-09-11 2011-01-15 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
ES2772674T3 (es) 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
KR101477824B1 (ko) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
JP6034696B2 (ja) 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
RU2597288C2 (ru) * 2011-02-23 2016-09-10 Ф. Хоффманн-Ля Рош Аг Антитела против человеческого il33r и их применение
PL2925350T3 (pl) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
RU2015123032A (ru) 2012-12-04 2017-01-11 Онкомед Фармасьютикалс, Инк. Иммунотерапия с применением связывающих агентов
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
MX2016000510A (es) * 2013-07-16 2016-04-07 Genentech Inc Metodos para tratar cancer utilizando antagonistas de union al eje pd-1 e inhibidores de tigit.
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
PE20170140A1 (es) 2014-07-16 2017-03-30 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
TN2017000024A1 (en) 2014-08-19 2018-07-04 Merck Sharp & Dohme Anti-tigit antibodies.
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
EP3237448A1 (fr) * 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Anticorps contre tigit
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3334757A4 (fr) 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. Anticorps anti-tigit
WO2017037707A1 (fr) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps spécifiques contre le domaine d'immunoglobuline de lymphocyte t et itim (tigit)
US20180251548A1 (en) 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
EP4360646A3 (fr) 2015-09-25 2024-05-15 F. Hoffmann-La Roche AG Anticorps anti-tigit et procédés d'utilisation
AR109625A1 (es) 2015-10-01 2019-01-09 Potenza Therapeutics Inc Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
TW202409084A (zh) 2016-03-04 2024-03-01 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法

Also Published As

Publication number Publication date
CN109071620A (zh) 2018-12-21
EP3303379A4 (fr) 2019-04-17
WO2016191643A3 (fr) 2017-01-12
MX2017014955A (es) 2018-04-13
EP3303379B1 (fr) 2021-10-13
KR20180014050A (ko) 2018-02-07
CN109071620B (zh) 2022-05-10
RS62815B1 (sr) 2022-02-28
JP6875295B2 (ja) 2021-05-19
WO2016191643A4 (fr) 2017-03-23
AU2016267577B2 (en) 2020-12-10
MA42622A (fr) 2018-06-20
US20160376365A1 (en) 2016-12-29
US10544219B2 (en) 2020-01-28
US10112997B2 (en) 2018-10-30
JP2021118719A (ja) 2021-08-12
SA517390370B1 (ar) 2021-09-12
BR112017025529A2 (pt) 2018-08-07
JP2018521634A (ja) 2018-08-09
CN115429877A (zh) 2022-12-06
ES2902150T3 (es) 2022-03-25
MD3303379T2 (ro) 2022-02-28
CA2987607A1 (fr) 2016-12-01
NZ738008A (en) 2019-08-30
ECSP17083779A (es) 2018-02-28
HUE057087T2 (hu) 2022-04-28
IL255577A (en) 2018-01-31
LT3303379T (lt) 2021-12-10
HRP20211948T1 (hr) 2022-03-18
SI3303379T1 (sl) 2022-01-31
AU2016267577A1 (en) 2017-12-21
CY1125260T1 (el) 2023-03-24
EP4011907A1 (fr) 2022-06-15
EP3303379A2 (fr) 2018-04-11
US20190077864A1 (en) 2019-03-14
PL3303379T3 (pl) 2022-02-07
TWI715587B (zh) 2021-01-11
TW201718646A (zh) 2017-06-01
IL255577B (en) 2022-02-01
CL2017003021A1 (es) 2018-06-01
WO2016191643A2 (fr) 2016-12-01
PT3303379T (pt) 2022-01-06
JP7203446B2 (ja) 2023-01-13
CO2017012342A2 (es) 2018-02-28
DK3303379T3 (da) 2021-12-06

Similar Documents

Publication Publication Date Title
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA45712A (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA43094B1 (fr) Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
MA53750A (fr) Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA44322A (fr) Compositions comprenant des souches bactériennes
MA39313B1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA42471A (fr) Compositions comprenant des souches bactériennes
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA40913A (fr) Conjugués anticorps-médicament
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA38478A1 (fr) Anticorps anti-pac1 humains
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA39342B2 (fr) Anticorps il -21
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b